# Formulary Adherence Checklist for NICE Technology Appraisals About Medicines

NHS Midlands and Lancashire Commissioning Support Unit

NHS Pan Mersey Area Prescribing Committee

This spreadsheet is updated monthly and details Pan Mersey APC adherence to current NICE Technology Appraisals.

All guidelines refer to adults unless indicated.

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| **2018-19** | | | | | | | | | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [TA572] | 27/03/2019 | Ertugliflozin as monotherapy is recommended as an option for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if:<br>•a dipeptidyl peptidase 4 (DPP-4) inhibitor would otherwise be prescribed and<br>•a sulfonylurea or pioglitazone is not appropriate.<br>Ertugliflozin in a dual-therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if:<br>•a sulfonylurea is contraindicated or not tolerated or<br>•the person is at significant risk of hypoglycaemia or its consequences. | x | | | 28/03/2019 | 26/04/2019 | 1 | CCG commissioned Green drug | Pan Mersey GREEN statement approved 27/03/19 |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib [TA571] | 20/03/2019 | Brigatinib is recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib. It is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 28/03/19 |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) [TA570] | 20/03/2019 | NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme. | | | x | | | | N/A | Link added to Pan Mersey formulary 28/03/19 |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer [TA569] | 20/03/2019 | Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults, only if:<br>•they have lymph node-positive disease<br>•the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 28/03/19 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) [TA568] | 13/03/2019 | NICE is unable to make a recommendation about the use in the NHS of abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because no evidence submission was received from Bristol–Myers Squibb. We will review this decision if the company decides to make a submission. | | | x | | | | N/A | Link added to Pan Mersey formulary 28/03/19 |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies [TA567] | 13/03/2019 | Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 28/03/19 |
| Cochlear implants for children and adults with severe to profound deafness [TA566] | 07/03/2019 | Unilateral cochlear implantation is recommended as an option for people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids. Simultaneous bilateral cochlear implantation is recommended as an option for the following groups of people with severe to profound deafness who do not receive adequate benefit from acoustic hearing aids. | | x | | | | | NHSE commissioned RED drug | Not a drug, therefore not added to Pan Mersey formulary |
| Benralizumab for treating severe eosinophilic asthma [TA565] | 06/03/2019 | Benralizumab, as an add-on therapy, is recommended as an option for treating severe eosinophilic asthma that is inadequately controlled in adults despite maintenance therapy with high-dose inhaled corticosteroids and long-acting beta-agonists, only if:<br>•the person has agreed to and followed the optimised standard treatment plan and<br>•the blood eosinophil count has been recorded as 300 cells per microlitre or more and the person has had 4 or more exacerbations needing systemic corticosteroids in the previous 12 months, or has had continuous oral corticosteroids of at least the equivalent of prednisolone 5 mg per day over the previous 6 months (that is, the person is eligible for mepolizumab) or<br>•the blood eosinophil count has been recorded as 400 cells per microlitre or more with 3 or more exacerbations needing systemic corticosteroids in the past 12 months (that is, the person is eligible for reslizumab).<br>Benralizumab is recommended only if the company provides it according to the commercial arrangement. | | | x | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 28/03/19 |
| Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) [TA564] | 27/02/2019 | | | | x | | | | N/A | Link added to Pan Mersey formulary 27/02/19 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer [TA563] | 27/02/2019 | Abemaciclib with an aromatase inhibitor is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults. Abemaciclib is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma [TA562] | 27/02/2019 | Encorafenib with binimetinib is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides encorafenib and binimetinib according to the commercial arrangements. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia [TA561] | 27/02/2019 | Venetoclax with rituximab is recommended, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy. It is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) [TA560] | 20/02/2019 | NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer because no evidence submission was received from Roche. We will review this decision if the company decides to make a submission. | | | x | | | | N/A | Link added to Pan Mersey formulary 27/02/19 |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [TA559] | 23/01/2019 | Axicabtagene ciloleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic therapies, only if the conditions in the managed access agreement are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease [TA558] | 23/01/2019 | Nivolumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease. It is recommended only if the conditions in the managed access agreement are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer [TA557] | 10/01/2019 | Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations. It is only recommended if:<br>•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and<br>•the company provides pembrolizumab according to the managed access agreement. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease [TA556] | 09/01/2019 | Darvadstrocel is not recommended, within its marketing authorisation, for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn's disease. | | | x | | | | N/A | Link added to Pan Mersey formulary 27/02/19 |
| Regorafenib for previously treated advanced hepatocellular carcinoma [TA555] | 09/01/2019 | Regorafenib is recommended as an option for treating advanced unresectable hepatocellular carcinoma in adults who have had sorafenib, only if:<br>•they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and<br>•the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 27/02/19 |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years [TA 554] | 21/12/2018 | Tisagenlecleucel therapy is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years, only if the conditions in the managed access agreement are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 17/01/19 |
| Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence [TA 553] | 19/12/2018 | Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for the adjuvant treatment of stage III melanoma with lymph node involvement in adults who have had complete resection. It is recommended only if the conditions in the managed access agreement for pembrolizumab are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 17/01/19 |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia [TA 552] | 19/12/2018 | Liposomal cytarabine–daunorubicin is recommended, within its marketing authorisation, as an option for untreated therapy-related acute myeloid leukaemia or acute myeloid leukaemia with myelodysplasia-related changes in adults. It is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 17/01/19 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Lenvatinib for untreated advanced hepatocellular carcinoma [TA 551] | 19/12/2018 | Lenvatinib is recommended as an option for untreated, advanced, unresectable hepatocellular carcinoma in adults, only if:<br>• they have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and<br>• the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 17/01/19 |
| Vandetanib for treating medullary thyroid cancer [TA 550] | 12/12/2018 | Vandetanib is not recommended, within its marketing authorisation, for treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease. | | | x | | | | N/A | Link added to Pan Mersey formulary 17/01/19 |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549) | 05/12/2018 | NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence submission was received from Amgen. | | | x | | | | N/A | Link added to Pan Mersey formulary 17/01/19 |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548) | 05/12/2018 | NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was received from Janssen. | | | x | | | | N/A | Link added to Pan Mersey formulary 17/01/19 |
| Tofacitinib for moderately to severely active ulcerative colitis [TA 547] | 28/11/2018 | Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment. It is recommended only if the company provides tofacitinib with the discount agreed in the commercial arrangement. | x | | | 31/01/2019 | 26/02/2019 | 64 | CCG commissioned PBRe RED drug | Pan Mersey RED statement approved 30/01 /2019 |
| Padeliporfin for untreated localised prostate cancer [TA 546] | 21/11/2018 | Padeliporfin is not recommended, within its marketing authorisation, for untreated, unilateral, low-risk prostate cancer in adults. | | | x | | | | N/A | Link added to Pan Mersey formulary 29/11/2018 |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia [TA 545] | 14/11/2018 | Gemtuzumab ozogamicin, with daunorubicin and cytarabine, is recommended as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia, in people 15 years and over, only if:<br>• they start induction therapy when either the cytogenetic test confirms that the disease has favourable, intermediate or unknown cytogenetics (that is, because the test was unsuccessful) or when their cytogenetic test results are not yet available and<br>• they start consolidation therapy when their cytogenetic test confirms that the disease has favourable, intermediate or unknown cytogenetics (because the test was unsuccessful) and<br>• the company provides gemtuzumab ozogamicin according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 29/11/2018 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma [TA544] | 17/10/2018 | Dabrafenib with trametinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of resected stage III BRAF V600 mutation-positive melanoma in adults. It is recommended only if the company provides dabrafenib and trametinib with the discounts agreed in the commercial arrangements. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 18/10/2018 |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [TA543] | 03/10/2018 | Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:<br>• it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or<br>• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or<br>• TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).<br>Tofacitinib is only recommended if the company provides it according to the commercial arrangement. | x | | | 29/11/2018 | 01/01/2019 | 57 | CCG commissioned PBRe RED drug | Pan Mersey RED statement approved 28/11/2018 |
| Cabozantinib for untreated advanced renal cell carcinoma [TA542] | 03/10/2018 | Cabozantinib is recommended, within its marketing authorisation, for adults with untreated advanced renal cell carcinoma that is intermediate- or poor-risk as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. It is recommended only if the company provides cabozantinib according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 18/10/2018 |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [TA541] | 19/09/2018 | Inotuzumab ozogamicin is recommended, within its marketing authorisation, as an option for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults. People with relapsed or refractory Philadelphia-chromosome-positive disease should have had at least 1 tyrosine kinase inhibitor.<br>Inotuzumab ozogamicin is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 18/10/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma [TA540] | 03/09/2018 | Pembrolizumab is not recommended for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had autologous stem cell transplant and brentuximab vedotin. Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating relapsed or refractory classical Hodgkin lymphoma in adults who have had brentuximab vedotin and cannot have autologous stem cell transplant, only if:<br>• pembrolizumab is stopped after 2 years of treatment or earlier if the person has a stem cell transplant or the disease progresses and<br>• the conditions in the managed access agreement for pembrolizumab are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 06/09/18 |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours [TA539] | 29/08/2018 | Lutetium (177Lu) oxodotreotide is recommended, within its marketing authorisation, as an option for treating unresectable or metastatic, progressive, well-differentiated (grade 1 or grade 2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (NETs) in adults. It is recommended only if the company provides it according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 30/08/18 |
| Dinutuximab beta for treating neuroblastoma [TA538] | 22/08/2018 | Dinutuximab beta is recommended as an option for treating high-risk neuroblastoma in people aged 12 months and over whose disease has at least partially responded to induction chemotherapy, followed by myeloablative therapy and stem cell transplant, only if:<br>• they have not already had anti-GD2 immunotherapy and<br>• the company provides dinutuximab beta according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 24/08/18 |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA537] | 08/08/2018 | Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if:<br>• it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or<br>• the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks or<br>• TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).<br>Ixekizumab is only recommended if the company provides it according to the commercial arrangement. | x | | | 27/09/2018 | 06/11/2018 | 50 | CCG commissioned PBRe RED drug | Pan Mersey RED statement approved 26/09/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer [TA536] | 08/08/2018 | Alectinib is recommended, within its marketing authorisation, as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults. It is recommended only if the company provides alectinib according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 24/08/18 |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [TA535] | 08/08/2018 | Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose disease does not respond to radioactive iodine, only if:<br>•t hey have not had a tyrosine kinase inhibitor before or<br>• they have had to stop taking a tyrosine kinase inhibitor within 3 months of starting it because of toxicity (specifically, toxicity that cannot be managed by dose delay or dose modification).<br>Lenvatinib and sorafenib are recommended only if the companies provide them according to the commercial arrangements. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 24/08/18 |
| Dupilumab for treating moderate to severe atopic dermatitis [TA534] | 01/08/2018 | Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:<br>• the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated<br>• the company provides dupilumab according to the commercial arrangement. | x | | | 27/09/2018 | 31/08/2018 | 57 | CCG commissioned PBRe RED drug | Pan Mersey RED statement approved 26/09/18 |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis [TA533] | 25/07/2018 | Ocrelizumab is recommended as an option for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features, only if:<br>• alemtuzumab is contraindicated or otherwise unsuitable and<br>• the company provides ocrelizumab according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 25/07/18 |
| Cenegermin for treating neurotrophic keratitis [TA532] | 18/07/2018 | Cenegermin is not recommended, within its marketing authorisation, for treating moderate or severe neurotrophic keratitis in adults. | | | x | | | | N/A | Link added to Pan Mersey formulary 19/07/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [TA531] | 18/07/2018 | Pembrolizumab is recommended as an option for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults whose tumours express PD-L1 (with at least a 50% tumour proportion score) and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations, only if:<br>• pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and<br>• the company provides pembrolizumab according to the commercial access agreement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 19/07/18 |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy [TA530] | 04/07/2018 | Nivolumab is not recommended, within its marketing authorisation, for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing therapy. | | | x | | | | N/A | Link added to Pan Mersey formulary 05/07/18 |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer [TA529] | 04/07/2018 | Crizotinib is recommended for use within the Cancer Drugs Fund as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if the conditions in the managed access agreement are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 05/07/18 |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA528] | 04/07/2018 | Niraparib is recommended for use within the Cancer Drugs Fund as an option for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to the most recent course of platinum-based chemotherapy in adults, only if:<br>•they have a germline BRCA mutation and have had 2 courses of platinum-based chemotherapy or<br>•they do not have a germline BRCA mutation and have had 2 or more courses of platinum-based chemotherapy and<br>•the conditions in the managed access agreement for niraparib are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 05/07/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Beta interferons and glatiramer acetate for treating multiple sclerosis [TA527] | 27/06/2018 | Interferon beta-1a is recommended as an option for treating multiple sclerosis, only if:<br>•the person has relapsing–remitting multiple sclerosis and<br>•the companies provide it according to commercial arrangements.<br>Interferon beta-1b (Extavia) is recommended as an option for treating multiple sclerosis, only if:<br>•the person has relapsing–remitting multiple sclerosis and has had 2 or more relapses within the last 2 years or<br>•the person has secondary progressive multiple sclerosis with continuing relapses and<br>•the company provides it according to the commercial arrangement.<br>Glatiramer acetate is recommended as an option for treating multiple sclerosis, only if:<br>•the person has relapsing–remitting multiple sclerosis and<br>•the company provides it according to the commercial arrangement.<br>Interferon beta-1b (Betaferon) is not recommended within its marketing authorisation as an option for treating multiple sclerosis. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 27/06/18 |
| Arsenic trioxide for treating acute promyelocytic leukaemia [TA526] | 13/06/2018 | Arsenic trioxide is recommended, within its marketing authorisation, as an option for inducing remission and consolidation in acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults with:<br>•untreated, low-to-intermediate risk disease (defined as a white blood cell count of 10x103 per microlitre or less), when given with all-trans-retinoic acid (ATRA)<br>•relapsed or refractory disease, after a retinoid and chemotherapy. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 13/06/18 |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA525] | 13/06/2018 | Atezolizumab is recommended as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:<br>•atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and<br>•the company provides atezolizumab with the discount agreed in the patient access scheme. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 13/06/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma [TA524] | 13/06/2018 | Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease, only if:<br>•they have already had autologous stem cell transplant or<br>•they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable and<br>•the company provides brentuximab vedotin according to the commercial arrangement. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 13/06/18 |
| Midostaurin for untreated acute myeloid leukaemia [TA523] | 13/06/2018 | Midostaurin is recommended, within its marketing authorisation, as an option in adults for treating newly diagnosed acute FLT3-mutation-positive myeloid leukaemia with standard daunorubicin and cytarabine as induction therapy, with high-dose cytarabine as consolidation therapy, and alone after complete response as maintenance therapy. It is recommended only if the company provides midostaurin with the discount agreed in the patient access scheme. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 13/06/18 |
| Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable [TA522] | 13/06/2018 | Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for untreated locally advanced or metastatic urothelial carcinoma in adults when cisplatin-containing chemotherapy is unsuitable, only if:<br>•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and<br>•the conditions of the managed access agreement for pembrolizumab are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 13/06/18 |
| Guselkumab for treating moderate to severe plaque psoriasis [TA521] | 13/06/2018 | Guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:<br>•the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and<br>•the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated and<br>•the company provides the drug according to the commercial arrangement. | x | | | 28/06/2018 | 13/07/18 | 15 | CCG commissioned PBRe RED drug | Pan Mersey RED statement approved 27/06/18 |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy[TA520] | 16/05/2018 | Atezolizumab is recommended as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK-positive tumour), only if:<br>•atezolizumab is stopped at 2 years of uninterrupted treatment or earlier if the disease progresses and<br>•the company provides atezolizumab with the discount agreed in the patient access scheme. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 18/05/18 |

| ***Technology appraisal (TA)*** Titles are hyperlinks to full guidance | ***Date of TA Release*** | ***Availability of medicine for NHS patients with this medical condition, as indicated by NICE*** | ***Adherence of APC formulary to NICE*** | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | ***CCG Commissioned*** *(mark 'x' if applicable)* | ***Non-CCG Commissioned*** *(mark 'x' if applicable)* | ***Not Applicable*** *(mark 'x' if applicable)* | ***Date of APC website upload*** | ***Implement by*** *(30/90 days of TA )* | ***Time to implement*** *(days)* | ***Notes*** *(e.g. rationale, method of making available)* | ***Pan Mersey Notes*** |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA519] | 25/04/2018 | Pembrolizumab is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy, only if:<br>•pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier in the event of disease progression and<br>•the conditions in the managed access agreement for pembrolizumab are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 27/04/18 |
| Tocilizumab for treating giant cell arteritis [TA518] | 18/04/2018 | Tocilizumab, when used with a tapering course of glucocorticoids (and when used alone after glucocorticoids), is recommended as an option for treating giant cell arteritis in adults, only if:<br>•they have relapsing or refractory disease<br>•they have not already had tocilizumab<br>•tocilizumab is stopped after 1 year of uninterrupted treatment at most and<br>•the company provides it with the discount agreed in the patient access scheme. | | x | | | | | NHSE commissioned RED drug | Link added to Pan Mersey formulary 24/04/18 |
| Avelumab for treating metastatic Merkel cell carcinoma [TA517] | 11/04/2018 | Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults, only if they have had 1 or more lines of chemotherapy for metastatic disease. Avelumab is recommended for use within the Cancer Drugs Fund as an option for treating metastatic Merkel cell carcinoma in adults, only if:<br>•they have not had chemotherapy for metastatic disease and<br>•the conditions in the managed access agreement for avelumab are followed. | | x | | | | | NHSE (CDF) commissioned RED drug | Link added to Pan Mersey formulary 13/04/18 |
| | | | 6 | 38 | | | | | | |
| | | | **% "Yes"** | **% "N/A"** | | _ | _ | **Average implement time** (days) | | |
| **Adherence statistics for 2018-19** | | | 100% | 100% | | | | **41** | | |